Skip to main content
PGIM Quantitative Solutions LogoPGIM Quantitative Solutions Logo
  • About Us
    • Our Philosophy
    • Our History
    • The Team
    • Diversity, Equity & Inclusion
    • Contact Us
  • All Insights
    • ESG
    • Market Views
  • ESG Overview
    • ESG Insights
    • ESG Policy
    • Stewardship and Governance
  • Overview of Solutions
    • Quantitative Equity
    • Multi Asset
    • PGIM Wadhwani
    • PGIM DC Solutions
  • Client Log In
  • Careers
QMA Global Multi-Asset
Market Views

The Trend Is Not The Pandemic's FriendTheTrendIsNotThePandemic'sFriend

By John Hall — Mar 5, 2021

5 mins

Share
  • Mail
  • LinkedIn
  • Twitter
  • Copy URL
Download PDF

Share

While the number of COVID-19 cases in the US remains high, the rate of infection has dropped significantly, providing hope that the worst of the pandemic may well be behind us and that the US economic recovery will pick up speed as the year unfolds.

Since reaching a peak in January following the holidays, new COVID-19 cases have plunged dramatically. According to the World Health Organization (WHO), the US had just over 470,000 new COVID-19 cases over the week ending February 28th. That is the fewest number of new cases in a week since late October and represents a 70% decline from the peak in January1.

While the plunge in cases is multi-faceted and complex2, the surge in vaccine administration is likely the most significant driver of the decline. (Figure 1 shows the significant ramp up in vaccine administration and the subsequent decline in new cases.)

Figure 1: US COVID-19 New Cases and Vaccines (7-day moving average)

Source: WHO, Johns Hopkins, QMA Calculations. As of 2/28/2021.

According to data from Johns Hopkins, as of February 28th, more than 72 million vaccines have been administered in the US, at a pace of roughly 1.7 million per day. The 18.8% of the adult population that has received one or more doses of the vaccine, combined with others who have recovered from the disease and acquired immunity, has significantly reduced the number of hosts available.

Moreover, according to analysis by Bloomberg3, the number of vaccines delivered should increase to “almost 20 million a week in March, more than 25 million a week in April and May, and over 30 million a week in June. By summer, it would be enough to give 4.5 million shots a day.” Also helping to get more vaccines in arms is Pfizer’s recent decision to ask the US Food and Drug Administration for permission to store vaccines at higher temperatures4, which will reduce the logistical difficulties in delivering the vaccine.

As more and more people are vaccinated, the number of new cases should continue to fall.

Already fewer people are dying from the disease. The WHO reports less than 15,000 people died from COVID-19 in the week ending February 28th. This is down more than 35% from the peak in January5.

Figure 2: US COVID-19 New Cases and Deaths (7-day moving average)

Source: WHO, QMA Calculations. As of 2/28/2021.

This trend is likely to accelerate due to the lag between falling cases and the number of deaths. The US FDA’s emergency use authorization of the Johnson & Johnson vaccine6 will help diversify vaccine supply, while prioritizing vaccine administration for the elderly7 and those with health issues is also likely to reduce the death rate. In addition, the lower case counts should free doctors to focus on more serious cases.

Thus, current trends in vaccine administration, cases, and deaths suggest that the worst is behind us.

Absent new shocks, the populations most at risk should be vaccinated (if they want) by March with the bulk of the US population vaccinated by the summer. Lockdowns and other governmental restrictions will either be re-evaluated or eliminated in response, opening up the economy significantly and paving the way for strong GDP growth in the second half of 2021, particularly from the services sector, which had been hit harder by lockdowns and restrictions than manufacturing.

Of course, new strains from the UK, South Africa, and Brazil that more easily spread the disease pose some risks to the outlook. The Pfizer and Moderna vaccines provide some protection against the UK strain but are less effective against the South African strain. Pharmaceutical companies are developing booster shots to protect against the new strains. While faster delivery of the original vaccines may be enough to limit the spread of the new strains in the US and other developed markets, lower-income countries with limited access to the vaccines may continue to see new COVID-19 infections for some time, providing a breeding ground for new strains and potentially necessitating regular, or even seasonal, booster shots against the latest COVID-19 strain.

1 Over 1,780,000 in the seven days ending January 13th.

2 Thompson, D. (2021, Feb. 17). COVID-19 Cases Are Dropping Fast. Why?. Retrieved from https://www.theatlantic.com/ideas/archive/2021/02/why-covid-19-cases-are-falling-so-fast/618041/.

3 Armstrong, D. & Randall, T. (2021, Feb. 2021). A U.S. Vaccine Surge Is Coming, With Millions of Doses Promised. Retrieved from https://www.bloomberg.com/news/articles/2021-02-18/how-many-vaccine-doses-are-available-u-s-should-see-a-surge.

4 Lovelace, Jr., B. (2021, Feb. 19). Pfizer asks FDA to approve storing Covid vaccine doses at higher temperatures. Retrieved from https://www.cnbc.com/2021/02/19/covid-vaccine-pfizer-asks-fda-to-approve-storing-doses-at-higher-temperatures.html.

5 Over 23,000 in the seven days ending January 28th.

6 U.S Food & Drug Administration (2021, Feb. 27). FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine.

7 According to the CDC, nearly 55% of vaccines administered have gone to those over 65. Retrieved February 22, 2021 from https://covid.cdc.gov/covid-data-tracker/#vaccination-demographic.

Download PDF
  • By John HallCFA & Vice President, PGIM Quantitative Solutions
  • About Us

    • Overview
    • Our Philosophy
    • Our History
    • The Team
    • Inclusion & Diversity
    • Contact Us
    • Careers
  • Insights

    • Overview
    • ESG
    • Market Views
  • ESG

    • Overview
    • Insights
    • ESG Policy
    • Stewardship and Governance
  • Solutions

    • Overview
    • Quantitative Equity
    • Multi Asset
    • PGIM Wadhwani
    • PGIM DC Solutions
PGIM Quantitative Solutions Logo
  • Terms & Conditions
  • Privacy Center
  • Accessibility Help
  • Cookie Preference Center

For Professional Investors only. All investments involve risk, including the possible loss of capital.

The content and materials presented here are for informational and educational purposes only and should not be construed as investment advice or an offer or solicitation in respect of any products or services to any persons who are prohibited from receiving such information under the laws applicable to their place of citizenship, domicile or residence. PGIM Quantitative Solutions LLC (PGIM Quantitative Solutions or PGIM Quant), formerly known as QMA LLC, is an SEC-registered investment adviser and a wholly-owned subsidiary of PGIM, Inc. (PGIM), the principal asset management business of Prudential Financial, Inc. (PFI) of the United States of America. Registration with the SEC does not imply a certain level of skill or training. PFI of the United States is not affiliated in any manner with Prudential plc incorporated in the United Kingdom or with Prudential Assurance Company, a subsidiary of M&G plc, incorporated in the United Kingdom. 

In the United Kingdom, information is issued by PGIM Limited with registered office: Grand Buildings, 1-3 Strand, Trafalgar Square, London, WC2N 5HR. PGIM Limited is authorised and regulated by the Financial Conduct Authority (“FCA”) of the United Kingdom (Firm Reference Number 193418). In the European Economic Area (“EEA”), information is issued by PGIM Netherlands B.V. with registered office: Gustav Mahlerlaan 1212, 1081 LA Amsterdam, The Netherlands. PGIM Netherlands B.V. is authorised by the Autoriteit Financiële Markten (“AFM”) in the Netherlands (Registration number 15003620) and operating on the basis of a European passport. In certain EEA countries, information is, where permitted, presented by PGIM Limited in reliance of provisions, exemptions or licenses available to PGIM Limited under temporary permission arrangements following the exit of the United Kingdom from the European Union. 

These materials are issued by PGIM Limited and/or PGIM Netherlands B.V. to persons who are professional clients as defined under the rules of the FCA and/or to persons who are professional clients as defined in the relevant local implementation of Directive 2014/65/EU (MiFID II). PGIM Quantitative Solutions, PGIM Limited and/or PGIM Netherlands B.V. are indirect, wholly-owned subsidiaries of PGIM. These materials are not intended for distribution to, or use by, any person in any jurisdiction where such distribution would be contrary to local or international law or regulation.

In Japan, investment management services are made available by PGIM Japan, Co. Ltd., ("PGIM Japan"), a registered Financial Instruments Business Operator with the Financial Services Agency of Japan. In Hong Kong, information is provided by PGIM (Hong Kong) Limited, a regulated entity with the Securities & Futures Commission in Hong Kong to professional investors as defined in Section 1 of Part 1 of Schedule 1 (paragraph (a) to (i) of the Securities and Futures Ordinance (Cap.571). In Singapore, information is issued by PGIM (Singapore) Pte. Ltd. (“PGIM Singapore”), a Singapore investment manager that is licensed as a capital markets service license holder by the Monetary Authority of Singapore and an exempt financial adviser. These materials are issued by PGIM Singapore for the general information of “institutional investors” pursuant to Section 304 of the Securities and Futures Act, Chapter 289 of Singapore (the “SFA”) and “accredited investors” and other relevant persons in accordance with the conditions specified in Sections 305 of the SFA. In South Korea, information is issued by PGIM Quantitative Solutions, which is licensed to provide discretionary investment management services directly to South Korean qualified institutional investors on a cross-border basis.

PGIM, PGIM Quantitative Solutions logo and the Rock design are service marks of PFI and its related entities, registered in many jurisdictions worldwide.

© 2022 PGIM Quantitative Solutions. All Rights Reserved.
 

You are viewing this page in preview mode.

Edit Page